AUPH
Aurinia Pharmaceuticals Inc.
AUPH has a slight edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
AUPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
AUPH's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AUPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.1x | $16.18 | -0.2% |
| Current | 7.1x | $16.21 | — |
| Forward | 19x | $16.21 | — |
| Fair | 26x | $59.75 | +269% |
| Expensive | 31x | $70.12 | +333% |
Historical ranges are pointers, not guarantees.
AUPH's PE is in its cheap range at 7.1x. On analysts' estimates for next year's earnings, today's price would be 19x, in its fair range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AUPH in the historical PE scenario, which offers more potential upside but is not a forecast.
AUPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect AUPH's revenue to grow, but its profitability to weaken.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AUPH on the outlook, with more favorable valuation and earnings expectations.
AUPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.83 | -64% |
| Q3 2026 | $2.29 | +309% |
| Q2 2026 | $2.29 | +433% |
| Q1 2026 | $2.17 | +675% |
| Q4 2025 | $2.08 | +4060% |
| Q3 2025 | $0.56 | +$0.71 |
| Q2 2025 | $0.43 | +$0.77 |
| Q1 2025 | $0.28 | +$0.71 |
| Q4 2024 | $0.05 | +$0.59 |
AUPH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AUPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.7M | +14% |
| Q2 2026 | $83.2M | +19% |
| Q1 2026 | $77.7M | +24% |
| Q4 2025 | $77.1M | +29% |
| Q3 2025 | $73.5M | +8.4% |
| Q2 2025 | $70M | +22% |
| Q1 2025 | $62.5M | +24% |
| Q4 2024 | $59.9M | +33% |
AUPH's revenue has grown year over year for 12 quarters in a row: $84M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | +1.8 points |
| Q2 2026 | 56% | +27 points |
| Q1 2026 | 53% | +18 points |
| Q4 2025 | 43% | +46 points |
| Q3 2025 | 40% | +23 points |
| Q2 2025 | 29% | +31 points |
| Q1 2025 | 35% | +61 points |
| Q4 2024 | -2.8% | +63 points |
AUPH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AUPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AUPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | +4.3% |
| Q2 2026 | $52.6M | +19% |
| Q1 2026 | $32.6M | +2405% |
| Q4 2025 | $45.7M | +52% |
| Q3 2025 | $44.4M | +161% |
| Q2 2025 | $44.2M | +179% |
| Q1 2025 | $1.3M | +$19.9M |
| Q4 2024 | $30.1M | +110% |
AUPH has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
AUPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | -0.6% | -835K shares |
| 3 years | -5.4% | -7.7M shares |
| 5 years | +5.2% | +6.7M shares |
| Available history | +38% | +37.2M shares |
AUPH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $38.7M |
| Q1 2026 | $36.2M |
| Q4 2025 | — |
| Q3 2025 | $8.7M |
| Q2 2025 | $42.6M |
| Q1 2025 | $46.9M |
| Q4 2024 | $21.8M |
AUPH spent $75M buying back its own shares over the past year, down 38% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AUPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
AUPH has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AUPH on leverage, with a lower net debt burden relative to earnings.
AUPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.9 | Neutral |
| Stochastic | 57.0 | Neutral |
AUPH's weekly RSI is 52 (neutral) and its Stochastic is 57 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AUPH PE vs Healthcare Sector
| Metric | AUPH | Sector median | Relative |
|---|---|---|---|
| PE | 7.1x | 26x | 73% below |
| PE % | 18 | 29 | 11 pts below |
AUPH has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AUPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.5 | 1.5% below |
| 20 week MA | $16.1 | 0.5% above |
| 50 week MA | $15.6 | 3.9% above |
| 100 week MA | $12.7 | 27% above |
| 200 week MA | $10.3 | 57% above |
AUPH's trend is up, with a small recent dip: it's below only its 8-week average, and 57% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AUPH on trend strength, trading above more of its moving averages.
AUPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.4 | $14.2 | -34% |
| 2021 | $14.2 | $23.1 | +63% |
| 2022 | $23.1 | $4.53 | -80% |
| 2023 | $4.53 | $8.99 | +98% |
| 2024 | $8.99 | $9.20 | +2.3% |
| 2025 | $9.20 | $16.3 | +77% |
| 2026 YTD | $16.3 | $16.2 | -0.2% |
AUPH has finished higher in four of the last six years, three of them by more than 50%. It's roughly flat so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AUPH on returns for 2026, with the stronger performance.